{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T17:29:15Z","timestamp":1784827755943,"version":"3.55.0"},"reference-count":36,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2016,11,1]],"date-time":"2016-11-01T00:00:00Z","timestamp":1477958400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","lipidjournal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Lipidology"],"published-print":{"date-parts":[[2016,11]]},"DOI":"10.1016\/j.jacl.2016.09.012","type":"journal-article","created":{"date-parts":[[2016,9,30]],"date-time":"2016-09-30T13:41:07Z","timestamp":1475242867000},"page":"1389-1396","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"title":["Lipoprotein(a)-cholesterol levels estimated by vertical auto profile correlate poorly with Lp(a) mass in hyperlipidemic subjects: Implications for clinical practice interpretation of Lp(a)-mediated risk"],"prefix":"10.1016","volume":"10","author":[{"given":"Calvin","family":"Yeang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul C.","family":"Clopton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sotirios","family":"Tsimikas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacl.2016.09.012_bib1","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1194\/jlr.M800174-JLR200","article-title":"A novel function of lipoprotein [a] as a preferential carrier of oxidized phospholipids in human plasma","volume":"49","author":"Bergmark","year":"2008","journal-title":"J Lipid Res"},{"key":"10.1016\/j.jacl.2016.09.012_bib2","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1194\/jlr.M040733","article-title":"Determinants of binding of oxidized phospholipids on apolipoprotein(a) and lipoprotein(a)","volume":"54","author":"Leibundgut","year":"2013","journal-title":"J\u00a0Lipid Res"},{"key":"10.1016\/j.jacl.2016.09.012_bib3","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1001\/jama.2009.1063","article-title":"Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality","volume":"302","author":"Erqou","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.jacl.2016.09.012_bib4","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1194\/jlr.R061648","article-title":"Lipoprotein (a) measurements for clinical application","volume":"57","author":"Marcovina","year":"2016","journal-title":"J Lipid Res"},{"key":"10.1016\/j.jacl.2016.09.012_bib5","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1001\/jama.2009.801","article-title":"Genetically elevated lipoprotein(a) and increased risk of myocardial infarction","volume":"301","author":"Kamstrup","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.jacl.2016.09.012_bib6","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1016\/j.jacc.2013.02.047","article-title":"Oxidation-specific biomarkers and risk of peripheral artery disease","volume":"61","author":"Bertoia","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2016.09.012_bib7","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1097\/HCO.0000000000000300","article-title":"Lipoprotein(a) and oxidized phospholipids in calcific aortic valve stenosis","volume":"31","author":"Yeang","year":"2016","journal-title":"Curr Opin Cardiol"},{"key":"10.1016\/j.jacl.2016.09.012_bib8","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1016\/j.jacc.2015.07.020","article-title":"Oxidized phospholipids, lipoprotein(a), and progression of calcific aortic valve stenosis","volume":"66","author":"Capoulade","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2016.09.012_bib9","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1139\/o86-133","article-title":"Isolation and partial characterization of apolipoprotein (a) from human lipoprotein (a)","volume":"64","author":"Seman","year":"1986","journal-title":"Biochem Cell Biol"},{"key":"10.1016\/j.jacl.2016.09.012_bib10","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1093\/clinchem\/46.12.1956","article-title":"Use of a reference material proposed by the International Federation of Clinical Chemistry and Laboratory Medicine to evaluate analytical methods for the determination of plasma lipoprotein(a)","volume":"46","author":"Marcovina","year":"2000","journal-title":"Clin Chem"},{"key":"10.1016\/j.jacl.2016.09.012_bib11","doi-asserted-by":"crossref","first-page":"8712","DOI":"10.1016\/S0021-9258(19)84439-3","article-title":"Physicochemical properties of apolipoprotein(a) and lipoprotein(a-) derived from the dissociation of human plasma lipoprotein (a)","volume":"261","author":"Fless","year":"1986","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jacl.2016.09.012_bib12","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1016\/j.jacc.2013.07.045","article-title":"Non-high-density lipoprotein cholesterol, guideline targets, and population percentiles for secondary prevention in 1.3 million adults: the VLDL-2 study (very large database of lipids)","volume":"62","author":"Elshazly","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2016.09.012_bib13","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1097\/MOL.0000000000000171","article-title":"'LDL-C'\u00a0= LDL-C\u00a0+ Lp(a)-C: implications of achieved ultra-low LDL-C levels in the proprotein convertase subtilisin\/kexin type 9 era of potent LDL-C lowering","volume":"26","author":"Yeang","year":"2015","journal-title":"Curr Opin Lipidol"},{"key":"10.1016\/j.jacl.2016.09.012_bib14","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/j.jacc.2014.03.061","article-title":"Discrimination and net reclassification of cardiovascular risk with lipoprotein(a): prospective 15-year outcomes in the Bruneck Study","volume":"64","author":"Willeit","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2016.09.012_bib15","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S0022-2275(20)40123-3","article-title":"Quantification of cholesterol in all lipoprotein classes by the VAP-II method","volume":"35","author":"Kulkarni","year":"1994","journal-title":"J Lipid Res"},{"key":"10.1016\/j.jacl.2016.09.012_bib16","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1016\/j.jacc.2008.03.003","article-title":"Lipid-altering efficacy and safety of ezetimibe\/simvastatin coadministered with extended-release niacin in patients with type IIa or type IIb hyperlipidemia","volume":"51","author":"Guyton","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2016.09.012_bib17","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.jacl.2016.01.005","article-title":"Effect of therapeutic interventions on oxidized phospholipids on apolipoprotein B100 and lipoprotein(a)","volume":"10","author":"Yeang","year":"2016","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacl.2016.09.012_bib18","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1016\/j.jacc.2010.04.048","article-title":"Oxidation-specific biomarkers, lipoprotein(a), and risk of fatal and nonfatal coronary events","volume":"56","author":"Tsimikas","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2016.09.012_bib19","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1194\/jlr.P066258","article-title":"Population and assay thresholds for the predictive value of lipoprotein (a) for coronary artery disease: the EPIC-Norfolk Prospective Population Study","volume":"57","author":"Verbeek","year":"2016","journal-title":"J\u00a0Lipid Res"},{"key":"10.1016\/j.jacl.2016.09.012_bib20","doi-asserted-by":"crossref","first-page":"673","DOI":"10.2217\/bmm.11.60","article-title":"Oxidized phospholipids on apolipoprotein B-100 (OxPL\/apoB) containing lipoproteins: a biomarker predicting cardiovascular disease and cardiovascular events","volume":"5","author":"Taleb","year":"2011","journal-title":"Biomark Med"},{"key":"10.1016\/j.jacl.2016.09.012_bib21","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1016\/j.jacc.2015.01.050","article-title":"Relationship of oxidized phospholipids on apolipoprotein B-100 to cardiovascular outcomes in patients treated with intensive versus moderate atorvastatin therapy: the TNT trial","volume":"65","author":"Byun","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2016.09.012_bib22","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1172\/JCI103182","article-title":"Distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum","volume":"34","author":"Havel","year":"1955","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.jacl.2016.09.012_bib23","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1194\/jlr.P027235","article-title":"Acute impact of apheresis on oxidized phospholipids in patients with familial hypercholesterolemia","volume":"53","author":"Arai","year":"2012","journal-title":"J Lipid Res"},{"key":"10.1016\/j.jacl.2016.09.012_bib24","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/BF02533209","article-title":"Immunochemical quantification of human plasma Lp(a) lipoprotein","volume":"9","author":"Albers","year":"1974","journal-title":"Lipids"},{"key":"10.1016\/j.jacl.2016.09.012_bib25","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1515\/CCLM.2004.114","article-title":"First WHO\/IFCC international reference reagent for lipoprotein(a) for immunoassay\u2013Lp(a) SRM 2B","volume":"42","author":"Dati","year":"2004","journal-title":"Clin Chem Lab Med"},{"key":"10.1016\/j.jacl.2016.09.012_bib26","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1016\/j.jacc.2013.06.051","article-title":"Relationship of apolipoproteins A-1 and B, and lipoprotein(a) to cardiovascular outcomes: the AIM-HIGH trial (Atherothrombosis Intervention in Metabolic Syndrome with Low HDL\/High Triglyceride and Impact on Global Health Outcomes)","volume":"62","author":"Albers","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2016.09.012_bib27","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/1475-2840-11-10","article-title":"Lp(a)-cholesterol is associated with HDL-cholesterol in overweight and obese African American children and is not an independent risk factor for CVD","volume":"11","author":"Sharma","year":"2012","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.jacl.2016.09.012_bib28","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.jacl.2012.01.004","article-title":"Lipoprotein(a) particle concentration and lipoprotein(a) cholesterol assays yield discordant classification of patients into four physiologically discrete groups","volume":"6","author":"Konerman","year":"2012","journal-title":"J\u00a0Clin Lipidol"},{"key":"10.1016\/j.jacl.2016.09.012_bib29","doi-asserted-by":"crossref","first-page":"2390","DOI":"10.1093\/hmg\/ddu731","article-title":"Evidence for several independent genetic variants affecting lipoprotein (a) cholesterol levels","volume":"24","author":"Lu","year":"2015","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.jacl.2016.09.012_bib30","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1194\/jlr.M056150","article-title":"Lipoprotein (a) upregulates ABCA1 in liver cells via scavenger receptor-B1 through its oxidized phospholipids","volume":"56","author":"Sharma","year":"2015","journal-title":"J Lipid Res"},{"key":"10.1016\/j.jacl.2016.09.012_bib31","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1161\/CIRCULATIONAHA.108.836940","article-title":"Relationship of oxidized phospholipids on apolipoprotein B-100 particles to race\/ethnicity, apolipoprotein(a) isoform size, and cardiovascular risk factors: results from the Dallas Heart Study","volume":"119","author":"Tsimikas","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2016.09.012_bib32","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1016\/j.jacc.2009.02.041","volume":"53","author":"Fraley","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2016.09.012_bib33","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1194\/jlr.M012526","article-title":"Lipoprotein(a) levels, apo(a) isoform size, and coronary heart disease risk in\u00a0the\u00a0Framingham Offspring Study","volume":"52","author":"Lamon-Fava","year":"2011","journal-title":"J Lipid Res"},{"key":"10.1016\/j.jacl.2016.09.012_bib34","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1016\/S0140-6736(15)61252-1","article-title":"Antisense therapy targeting apolipoprotein(a): a randomised, double-blind, placebo-controlled phase 1 study","volume":"386","author":"Tsimikas","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.jacl.2016.09.012_bib35","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1016\/j.jacc.2014.01.006","article-title":"Reduction in lipoprotein(a) with PCSK9 monoclonal antibody evolocumab (AMG 145): a pooled analysis of more than 1,300 patients in 4 phase II trials","volume":"63","author":"Raal","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2016.09.012_bib36","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.amjcard.2014.05.060","article-title":"Effect of alirocumab, a monoclonal proprotein convertase subtilisin\/kexin 9 antibody, on lipoprotein(a) concentrations (a pooled analysis of 150 mg every two weeks dosing from phase 2 trials)","volume":"114","author":"Gaudet","year":"2014","journal-title":"Am J Cardiol"}],"container-title":["Journal of Clinical Lipidology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287416303427?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287416303427?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,7,9]],"date-time":"2022-07-09T13:30:44Z","timestamp":1657373444000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1933287416303427"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11]]},"references-count":36,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2016,11]]}},"alternative-id":["S1933287416303427"],"URL":"https:\/\/doi.org\/10.1016\/j.jacl.2016.09.012","relation":{},"ISSN":["1933-2874"],"issn-type":[{"value":"1933-2874","type":"print"}],"subject":[],"published":{"date-parts":[[2016,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lipoprotein(a)-cholesterol levels estimated by vertical auto profile correlate poorly with Lp(a) mass in hyperlipidemic subjects: Implications for clinical practice interpretation of Lp(a)-mediated risk","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Lipidology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacl.2016.09.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 National Lipid Association. All rights reserved.","name":"copyright","label":"Copyright"}]}}